New data for amlitelimab published in JACI

New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped.

The drug is being developed by French drug major Sanofi (Euronext: SAN), which gained rights to amlitelimab through its up to $1.5 billion buy of British privately-held biotech Kymabin 2021. Sanofi has previously touted amlitelimab as one of 12 potential blockbusters in its immunology pipeline.

Results from the Phase IIb STREAM-AD trial, evaluating amlitelimab (formerly KY1005) in adult patients with moderate-to-severe atopic dermatitis, demonstrated amlitelimab’s potential to be an effective treatment option and support the viability of extended dosing every 12 weeks, which is currently being investigated in the robust Phase III clinical trial program OCEANA.